분자유전학실험실 (단국대학교 분자생물학과)



 이성욱 ( 2017-09-01 09:44:52 , Hit : 691
 First CAR T-Cell Therapy Approved in U.S.

The Scientist »
The Nutshell

http://www.the-scientist.com/?articles.view/articleNo/50231/title/First-CAR-T-Cell-Therapy-Approved-in-U-S-/&utm_campaign=NEWSLETTER_TS_The-Scientist-Daily_2016&utm_source=hs_email&utm_medium=email&utm_content=55843454&_hsenc=p2ANqtz-9X__FTJkvm1fbmiaGryJQJBBTqBqgFAYu4aL3cWVIz1oRoLd2CUGqUWRLFb7t17z8OXYx1oIdhYo4QTd_VIwIZArL3EA&_hsmi=55843454/


The genetically modified blood cells will be used for patients with a type of acute lymphoblastic leukemia, when other treatments fail.

By Shawna Williams | August 30, 2017


Each patient’s T-cells will be harvested from the body and genetically programmed to target leukemia cells.


The US Food and Drug Administration (FDA) announced today (August 30) that it has approved the first therapy involving chimeric antigen receptor (CAR) T cells for clinical use. Each dose of Novartis’s drug, Kymriah, will consist of a patient’s own white blood cells, harvested from the body and genetically programmed to seek an antigen on the surface of leukemia cells.

“We’re entering a new frontier in medical innovation with the ability to reprogram a patient’s own cells to attack a deadly cancer,” says FDA Commissioner Scott Gottlieb in a statement. “New technologies such as gene and cell therapies hold out the potential to transform medicine and create an inflection point in our ability to treat and even cure many intractable illnesses.”

Kymriah is approved for patients 25 years old and younger who have B-cell acute lymphoblastic leukemia, and whose disease has relapsed at least twice or is still detectable after other treatment. In a clinical trial, the therapy left 83 percent of such patients cancer-free after three months. STAT notes that only a few hundred patients per year may be eligible for the cell therapy. Priced at $475,000, it will be offered at just 32 sites around the country.

See “The CAR T-Cell Race”

Despite the limited use of Kymriah, the approval ushers in “a new approach to the treatment of cancer and other serious and life-threatening diseases,” FDA says. Business Insider reports that at an FDA meeting last month, oncologist Tim Cripe of Nationwide Children’s Hospital called Kymriah “the most exciting thing I’ve seen in my lifetime.”







1227   DNA Repair Mechanism Aids Cancer by Mending Chemo Damage  이성욱 2017/11/10 569
1226   Alcoholism Gene Therapy Shows Promise  이성욱 2017/09/20 583
1225   CRISPR Used in Human Embryos to Probe Gene Function  이성욱 2017/09/22 584
1224   [바이오토픽] CRISPR 기반 유전자치료를 방해하는 면역계  이성욱 2018/01/10 591
1223   암 면역요법, 일부 환자에게만 효과 있는 이유  이성욱 2018/01/12 591
1222   Nature Methods retracts CRISPR study  이성욱 2018/04/10 600
1221   From Startups to Moguls] CRISPR 유전자가위 없이 편집한다? Homology Medicines  이성욱 2017/09/11 607
1220   FDA Approves Gilead CAR-T Therapy Yescarta, Plans Regenerative Medicine Policy 'Soon'  이성욱 2017/10/20 610
1219   Severe Toxicity Reported in High-Dose AAV Gene Therapy in Animals  이성욱 2018/02/01 614
1218   CRISPR System Targets RNA in Mammalian Cells  이성욱 2017/10/06 641
1217   DNA Construction  이성욱 2017/09/15 661
1216   Advisors to FDA Recommend Approval of Gene Therapy for Blindness  이성욱 2017/10/14 666
1215   2018 Lasker Award Winners: Gene Expression Researchers, Propofol Discoverer, Pioneer for RNA Biology, and Women in STEM  이성욱 2018/09/12 671
1214   [바이오토픽] 체크포인트 저해제의 부작용: 자가면역질환 초래  이성욱 2017/11/16 689
  First CAR T-Cell Therapy Approved in U.S.  이성욱 2017/09/01 691
1212   UPDATED: FDA ushers in a new era in cancer treatment with ‘historic’ CAR-T approval for Novartis  이성욱 2017/08/31 696
1211   [바이오 업계 소식: From Startups to Moguls] CRISPR-Cas9에 대한 경고와 업계 반응  이성욱 2017/06/14 702
1210   Tunable Form of CRISPR Is an Efficient Regulator of Stem Cell Expression  이성욱 2016/03/14 703
1209   Mammalian Immunity: What’s RNAi Got to Do with It?  이성욱 2017/07/25 705
1208   코오롱 인보사허가  이성욱 2017/07/12 706

[1][2] 3 [4][5][6][7][8][9][10]..[64] [다음 10개]
 

Copyright 1999-2021 Zeroboard / skin by ROBIN